DOCSLIB.ORG

Interactions Between Antihypertensive Drugs and Food B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1866 Nutr Hosp. 2012;27(5):1866-1875 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Interactions between antihypertensive drugs and food B. Jáuregui-Garrido1 and I. Jáuregui-Lobera2 1Department of Cardiology. University Hospital Virgen del Rocío. Seville. Spain. 2Bromatology and Nutrition. Pablo de Olavide University. Seville. Spain. Abstract INTERACCIONES ENTRE FÁRMACOS ANTIHIPERTENSIVOS Y ALIMENTOS Objective: A drug interaction is defined as any alter- ation, pharmacokinetics and/or pharmacodynamics, Resumen produced by different substances, other drug treatments, dietary factors and habits such as drinking and smoking. Objetivo: la interacción de medicamentos se define como These interactions can affect the antihypertensive drugs, cualquier alteración, farmacocinética y/o farmacodiná- altering their therapeutic efficacy and causing toxic mica, producida por diferentes sustancias, otros tratamien- effects. The aim of this study was to conduct a review of tos, factores dietéticos y hábitos como beber y fumar. Estas available data about interactions between antihyperten- interacciones pueden afectar a los fármacos antihipertensi- sive agents and food. vos, alterando su eficacia terapéutica y causando efectos Methods: The purpose of this review was to report an tóxicos. El objetivo de este estudio fue realizar una revisión update of main findings with respect to the interactions de los datos disponibles acerca de las interacciones entre los between food and antihypertensive drugs by way of a fármacos antihipertensivos y los alimentos. search conducted in PubMed, which yielded a total of 236 Métodos: El objetivo de esta revisión fue proporcionar articles initially. una puesta al día sobre los principales resultados con res- Results: After excluding different articles, which were pecto a las interacciones entre alimentos y fármacos antihi- not focusing on the specific objective, the main results pertensivos mediante una búsqueda realizada en PubMed, refer to interactions between antihypertensive drugs and que dio lugar inicialmente a un total de 236 artículos. food (in general) as well as between antihypertensive Resultados: Tras la exclusión de diferentes artículos agents and grapefruit juice. que no estaban centrados en el objetivo específico, los Discussion: Food may affect the bioavailability of anti- resultados principales se refieren a las interacciones entre hypertensive drugs and this should be carefully consid- los fármacos antiarrítmicos y alimentos en general y ered. Advising patients to remove the grapefruit juice entre dichos fármacos y el zumo de pomelo. from their diet when treatment with these drugs seems to Discusión: Los alimentos pueden afectar a la biodispo- be the best recommendation. Given these interactions nibilidad de los fármacos antihipertensivos y ello debe ser and the associated potential adverse effects the anamnesis considerado cuidadosamente. Advertir a los pacientes must include detailed information about the specific que supriman el zumo de pomelo en su dieta cuando están eating habits of the patients. en tratamiento con estos fármacos parece la mejor reco- (Nutr Hosp. 2012;27:1866-1875) mendación. Dadas estas interacciones y sus potenciales efectos adversos, la anamnesis debe incluir información DOI:10.3305/nh.2012.27.6.6127 detallada sobre los hábitos alimentarios de los pacientes. Key words: Antihypertensive drugs. Food-drugs interac- (Nutr Hosp. 2012;27:1866-1875) tions. Grapefruit juice. Diet. DOI:10.3305/nh.2012.27.6.6127 Palabras clave: Fármacos antihipertensivos. Interacciones entre alimentos y medicamentos. Zumo de pomelo. Dieta. Abbreviations AT1 receptor: Angiotensin 1 receptor. AUC: Area under the curve (Area under the plasma ACE: Angiotensin-converting enzyme. concentration time curve). ARBs: Angiotensin II receptor blockers. BA: Bioavailability. BP: Blood pressure. Correspondence: I. Jáuregui-Lobera. Cmax: Maximum plasma concentration. Bromatology and Nutrition. cGMP: cyclic guanosine monophosphate. Pablo de Olavide University. CYP: Cytochrome P450 gene family. Virgen del Monte, 31. 41011 Seville. Spain. DASH: Dietary Approach to Stop Hypertension. E-mail: [email protected] / [email protected] DBP: Diastolic blood pressure. Recibido: 21-VIII-2012. HT: Hypertension. Aceptado: 24-VIII-2012. IP3: Inositol triphosphate. 1866 11. INTERACTIONS:01. Interacción 29/11/12 14:38 Página 1867 NaCl: Sodium chloride, common salt. and inhibitors of the CYP system, so the association of OAT: Organic anion transporter. antihypertensive drugs with other drugs and/or food OCT: Organic cation transporter. which use the CYP for their metabolism may be toxic. P-gp: P-glycoprotein. Together with CYP, it should be noted, due to its meta- SBP: Systolic blood pressure. bolic importance, the P-glycoprotein (P-gp), a family of t1/2: Drug elimination half-life. membrane transporters located in the brush border of the tmax: Time after administration of a drug when the enterocytes’ membranes. In addition to mobilizing maximum plasma concentration is reached. endogenous substances, the P-gp mobilizes certain drugs including some antihypertensive drugs.9-11 Drug interactions are defined as any alteration, phar- Introduction macokinetics and/or pharmacodynamics, produced by different substances, other drug treatments, dietary Hypertension (HT), which is defined as a chronic factors and habits such as drinking and smoking.12 elevation of systolic and/or diastolic blood pressure These interactions may affect the antihypertensive (BP), is in all probability the most common chronic drugs, modifying their therapeutic efficacy and the disease today. The main clinical significance of HT, adverse effects. which is not a disease in the usual sense of the word, The aim of this study was to conduct a review of lies on the future risk of vascular disease. Apart from available data about interactions between antihyper- various causes of HT, the most frequent case is the tensive drugs and food. essential HT (up to 95%).1,2 In the regulation of BP, there are different involving factors (sympathetic nervous system, kidney, hormonal Method systems), one of them being the composition of the diet. Thus, sodium, potassium, magnesium, lipids and total The review was conducted through a PubMed search. energy intake influence the control of BP.3 In the largest The initial search term was “Interactions between antihy- international study on the relationship between sodium pertensive drugs and food,” which resulted in a total of and BP (INTERSALT),4 the analysis of more than 337 articles. Later, other specific searches were 10,000 participants showed that a variation of 100 mmol performed, by entering “ Interactions between loop sodium intake modified the systolic BP (SBP) 2.2 diuretics and food”, “ Interactions between calcium mmHg, being lower the effect on diastolic BP (DBP). As channel blockers and food”, “Interactions between ACE for diet, one of the most relevant studies (DASH: Dietary inhibitors and food”, “Interactions between ARBs and Approaches to Stop Hypertension)5 showed that BP food”, “Interactions between hydralazine and food” and levels decreased with a diet low in saturated fat, choles- “Interactions between grapefruit juice and antihyperten- terol and total fat and high in fruits, vegetables and sive agents”. Having excluded the repeated articles, a total skimmed or semi-skimmed milk, that is a diet rich in of 236 articles were considered. Then those that did not magnesium, calcium, potassium, protein and fibre. In a make specific reference to the object of the review were later study (DASH-sodium),6 it was observed that with rejected. Articles without an abstract were also excluded. any level of sodium, the greatest reduction in BP was With respect to case reports and letters, because of the achieved with the DASH diet and even better with a scarcity of articles focusing specifically on a subject, sodium intake of only 1,500 mg of sodium per day. some of them were considered. Apart from the articles Regarding the treatment of HT, it is correct when its included after the search, some other articles and/or chap- continued efficacy is proven and it has minimal side ters were considered due to its relevance. effects. The goal is to achieve and maintain a SBP below 140 mmHg and a DBP below 90 mmHg.7 Apart from general measures of treatment (stress manage- Results ment, moderate salt restriction, regular exercise and moderate reduction of other risk factors) 8 there is a full Interactions between food and diuretics arsenal of antihypertensive drugs: diuretics, alpha and beta-blockers, calcium channel blockers, angiotensin- The simultaneous intake of food and some loop converting enzyme (ACE) inhibitors, angiotensin II diuretics such as furosemide and bumetanide causes a receptor blockers (ARBs) and others such as sodium decrease of the BA of these drugs, which in the case of nitroprusside, monoxidine, hydralazine and minoxidil. furosemide seems to be very high (approximately With regard to the bioavailability (BA) of antihyper- 30%).13 In a review, Bard et al. corroborated the exis- tensive drugs, it is noted the importance of the tence of a decrease in the BA of loop diuretics when cytochrome P450, a family of enzymes (encoded by the administered orally with food, although, only one gene CYP) located in the liver and gastrointestinal tract, study found a decrease in urinary excretion of these which represents the major source of metabolic activity drugs after taken
Recommended publications
  • Product List March 2019 - Page 1 of 53

    Product List March 2019 - Page 1 of 53

    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Summary of Product Characteristics

    Summary of Product Characteristics

    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT *IPERTEN/ARTEDIL/MANYPER 10mg tablets IPERTEN/ARTEDIL/MANYPER 20mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION IPERTEN/ARTEDIL/MANYPER 10 mg tablets Each tablet contains: Manidipine hydrochloride 10mg Excipient with known effect: 119,61 mg lactose monohydrate/tablet IPERTEN/ARTEDIL/MANYPER 20 mg tablets Each tablet contains: Manidipine hydrochloride 20mg Excipient with known effect: 131,80 mg lactose monohydrate/tablet For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet IPERTEN/ARTEDIL/MANYPER 10mg: pale yellow, round, scored tablet; IPERTEN/ARTEDIL/MANYPER 20mg: yellow-orange, oblong, scored tablet. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Mild to moderate essential hypertension 4.2 Posology and method of administration The recommended starting dose is 10 mg once a day. Should the antihypertensive effect be still insufficient after 2-4 weeks of treatment, it is advisable to increase the dosage to the usual maintenance dose of 20 mg once a day. Elderly In view of the slowing down of metabolism in the elderly, the recommended dose is 10mg once daily. This dosage is sufficient in most elderly patients; the risk/benefit of any dose increase should be considered with caution on an individual basis. Renal impairment In patients with mild to moderate renal dysfunction care should be taken when increasing the dosage from 10 to 20mg once a day. Hepatic impairment Due to the extensive hepatic metabolisation of manidipine, patients with mild hepatic dysfunction should not exceed 10mg once a day (see also Section 4.3 Contraindications). Tablet must be swallowed in the morning after breakfast, without chewing it, with a few liquid.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Accupril® (Quinapril Hydrochloride Tablets)

    Accupril® (Quinapril Hydrochloride Tablets)

    Accupril® (Quinapril Hydrochloride Tablets) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue ACCUPRIL as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION ACCUPRIL® (quinapril hydrochloride) is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C25H30N2O5 •HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. ACCUPRIL tablets contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. Each tablet also contains candelilla wax, crospovidone, gelatin, lactose, magnesium carbonate, magnesium stearate, synthetic red iron oxide, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angiotensin II, norepinephrine or epinephrine. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex, thereby facilitating renal sodium and fluid reabsorption.
  • The Repurposing Drugs in Oncology Database

    The Repurposing Drugs in Oncology Database

    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
  • Quinapril Tablets USP8289921/0720Frx Only

    Quinapril Tablets USP8289921/0720Frx Only

    QUINAPRIL- quinapril tablet American Health Packaging ---------- Quinapril Tablets USP 8289921/0720F Rx only WARNING: FETAL TOXICITY When pregnancy is detected, discontinue quinapril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity DESCRIPTION Quinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a non- sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)], 3R*]]-2-[2-[[1- (ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3- isoquinolinecarboxylic acid, monohydrochloride. Its empirical formula is C 25H 30N 2O 5•HCl and its structural formula is: Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. Quinapril tablets USP contain 5 mg (equivalent to 5.416 mg Quinapril Hydrochloride), 10 mg (equivalent to 10.832 mg Quinapril Hydrochloride), 20 mg (equivalent to 21.664 mg Quinapril Hydrochloride), or 40 mg (equivalent to 43.328 mg Quinapril Hydrochloride) of quinapril for oral administration. Each film-coated tablet also contains crospovidone, iron oxide yellow, lecithin, magnesium carbonate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, povidone, talc, titanium dioxide and xanthan gum. CLINICAL PHARMACOLOGY Mechanism of Action Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation.
  • (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn Et Al

    (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn Et Al

    USOO6784177B2 (12) United States Patent (10) Patent No.: US 6,784,177 B2 Cohn et al. (45) Date of Patent: Aug. 31, 2004 (54) METHODS USING HYDRALAZINE Massie et al., The American Journal of Cardiology, COMPOUNDS AND SOSORBIDE 40:794-801 (1977). DINTRATE OR ISOSORBIDE Kaplan et al., Annals of Internal Medicine, 84:639-645 MONONTRATE (1976). Bauer et al., Circulation, 84(1):35-39 (1991). (75) Inventors: Jay N. Cohn, Minneapolis, MN (US); The SOLVD Investigators, The New England Journal of Medicine, 327(10):685–691 (1992). Peter Carson, Chevy Chase, MD (US) Ziesche et al., Circulation, 87(6):VI56-VI64 (1993). Rector et al., Circulation, 87(6):VI71-VI77 (1993). (73) Assignee: Nitro Med, Inc., Bedford, MA (US) Carson et al., Journal of Cardiac Failure, 5(3):178-187 (Sep. 10, 1999). (*) Notice: Subject to any disclaimer, the term of this Dries et al, The New England Journal of Medicine, patent is extended or adjusted under 35 340(8):609-616 (Feb. 25, 1999). U.S.C. 154(b) by 18 days. Freedman et al, Drugs, 54 (Supplement 3):41-50 (1997). Sherman et al., Cardiologia, 42(2):177-187 (1997). (21) Appl. No.: 10/210,113 Biegelson et al., Coronary Artery Disease, 10:241-256 (1999). (22) Filed: Aug. 2, 2002 Rudd et al, Am. J. Physiol., 277(46):H732–H739 (1999). (65) Prior Publication Data Hammerman et al, Am. J. Physiol., 277(46):H1579–1592 (1999). US 2004/0023967 A1 Feb. 5, 2004 LoScalzo et al., Transactions of the American and Climato logical ASS., 111:158-163 (2000).
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • Pharmacodynamic Evaluation of Β-Blockade Associated with Atenolol

    Pharmacodynamic Evaluation of Β-Blockade Associated with Atenolol

    Pharmacodynamic HYDOXDWLRQRIȕ-blockade associated with atenolol in healthy dogs Mari Waterman Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences Jonathan A. Abbott, Chair Andrea C. Eriksson Jeffrey R. Wilcke July 30, 2018 Blacksburg, VA .H\ZRUGVDWHQROROȕ-blockade, isoproterenol, dog, pharmacodynamic Copyright 2018 Mari Waterman Pharmacodynamic HYDOXDWLRQRIȕ-blockade associated with atenolol in healthy dogs Mari Waterman ABSTRACT Objective: Dosing intervals of 12 and 24 hours for atenolol have been recommended, but an evidentiary basis is lacking. To test the hypothesis that repeated, once-daily oral administration of atenolol attenuates the heart rate response to isoproterenol for 24 hours, we performed a double-blind, randomized, placebo-controlled cross-over experiment. Animals: Twenty healthy dogs Procedures: Dogs were randomly assigned to receive either placebo (P) and then atenolol (A), [1 mg/kg PO q24h] or vice versa. Treatment periods were 5-7 days; time between periods was 7 days. Heart rates (bpm) at rest (HRr DQG GXULQJ FRQVWDQW UDWH > ȝJNJPLQ@ LQIXVLRQ RI isoproterenol (HRi) were electrocardiographically obtained 0, 0.25, 3, 6, 12, 18, and 24 hours after final administration of drug or placebo. A mixed model ANOVA was used to evaluate the effects of treatment (Tr), time after drug or placebo administration (t), interaction of treatment and time (Tr*t) as well as period and sequence on HRr and HRi. Results: Sequence or period effects were not detected. There was a significant effect of Tr (p <0.0001) and Tr*t (p <0.0001) on HRi.
  • Guidelines of Hypertension – 2020 Barroso Et Al

    Guidelines of Hypertension – 2020 Barroso Et Al

    Brazilian Guidelines of Hypertension – 2020 Barroso et al. Guidelines Brazilian Guidelines of Hypertension – 2020 Development: Department of Hypertension of the Brazilian Society of Cardiology (DHA-SBC), Brazilian Society of Hypertension (SBH), Brazilian Society of Nephrology (SBN) Norms and Guidelines Council (2020-2021): Brivaldo Markman Filho, Antonio Carlos Sobral Sousa, Aurora Felice Castro Issa, Bruno Ramos Nascimento, Harry Correa Filho, Marcelo Luiz Campos Vieira Norms and Guidelines Coordinator (2020-2021): Brivaldo Markman Filho General Coordinator: Weimar Kunz Sebba Barroso Coordination Work Group: Weimar Kunz Sebba Barroso, Cibele Saad Rodrigues, Luiz Aparecido Bortolotto, Marco Antônio Mota-Gomes Guideline Authors: Weimar Kunz Sebba Barroso,1,2 Cibele Isaac Saad Rodrigues,3 Luiz Aparecido Bortolotto,4 Marco Antônio Mota-Gomes,5 Andréa Araujo Brandão,6 Audes Diógenes de Magalhães Feitosa,7,8 Carlos Alberto Machado,9 Carlos Eduardo Poli-de-Figueiredo,10 Celso Amodeo,11 Décio Mion Júnior,12 Eduardo Costa Duarte Barbosa,13 Fernando Nobre,14,15 Isabel Cristina Britto Guimarães,16 José Fernando Vilela- Martin,17 Juan Carlos Yugar-Toledo,17 Maria Eliane Campos Magalhães,18 Mário Fritsch Toros Neves,6 Paulo César Brandão Veiga Jardim,2,19 Roberto Dischinger Miranda,11 Rui Manuel dos Santos Póvoa,11 Sandra C. Fuchs,20 Alexandre Alessi,21 Alexandre Jorge Gomes de Lucena,22 Alvaro Avezum,23 Ana Luiza Lima Sousa,1,2 Andrea Pio-Abreu,24 Andrei Carvalho Sposito,25 Angela Maria Geraldo Pierin,24 Annelise Machado Gomes de Paiva,5 Antonio
  • Ovid MEDLINE(R)

    Ovid MEDLINE(R)

    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil